In his research, Beat Christen, Professor of Experimental Systems Biology and researchers in the Christen Lab, ETH Zurich in Zurich, Switzerland use a digital genome design algorithm in conjunction with large-scale chemical DNA synthesis to physically produce artificial genomes and understand the code of life at the molecular level. The lab also uses systems and synthetic biology approaches to define essential genes across species that serve as the genetic parts to build microbial genomes for applications in sustainable chemistry, medicine and agriculture.

The research team has physically produced Caulobacter ethensis-2.0, the world’s first fully computer-generated genome. Using a natural freshwater bacterium as a starting point, the researchers computed the ideal DNA sequence for chemical manufacturing and construction of a minimized genome solely comprised of essential functions. In the design process, more than one-sixth of all of the 800,000 DNA letters in the artificial genome were replaced and the entire genome was produced as a large ring-shaped DNA molecule. While a living cell does not yet exist, gene functions have been tested across the entire genome design. In these experiments, researchers found out that approximately 580 of the 680 artificial genes were functional demonstrating the promise of the approach to produce designer genomes.

During the AAAS 2020 session, “Synthetic Biology: Digital Design of Living Systems” (February 14th, 2020 at 3:30 PM PST), Christen will discuss possible future applications of synthetic genomes for industrial purposes and health benefits. He will also talk about the need for profound discussions in society about the challenges and purposes for which this technology can be used and, at the same time, about how potential for abuse can be prevented.

Professor Christen will be joined by Professor David Baker, University of Washington who will speak about Designer Proteins and Joyce Tait, University of Edinburgh, Edinburgh Scotland, who will speak on Risk Regulation, Uncertainty, and Ethics.

Story Source:

Materials provided by ETH Zurich. Note: Content may be edited for style and length.

New approaches will not only expand upon but also go beyond the traditional SETI technique of searching for intelligently-generated radio signals, first pioneered by Frank Drake’s Project Ozma in 1960. Scientists now are designing state-of-the-art techniques to detect a variety of signatures that can indicate the possibility of extraterrestrial technologies. Such “technosignatures” can range from the chemical composition of a planet’s atmosphere, to laser emissions, to structures orbiting other stars, among others.

The National Radio Astronomy Observatory (NRAO) and the privately-funded SETI Institute announced an agreement to collaborate on new systems to add SETI capabilities to radio telescopes operated by NRAO. The first project will develop a system to piggyback on the National Science Foundation’s Karl G. Jansky Very Large Array (VLA) that will provide data to a state-of-the-art technosignature search system.

“As the VLA conducts its usual scientific observations, this new system will allow for an additional and important use for the data we’re already collecting,” said NRAO Director Tony Beasley. “Determining whether we are alone in the Universe as technologically capable life is among the most compelling questions in science, and NRAO telescopes can play a major role in answering it,” Beasley continued.

“The SETI Institute will develop and install an interface on the VLA permitting unprecedented access to the rich data stream continuously produced by the telescope as it scans the sky,” said Andrew Siemion, Bernard M. Oliver Chair for SETI at the SETI Institute and Principal Investigator for the Breakthrough Listen Initiative at the University of California, Berkeley. “This interface will allow us to conduct a powerful, wide-area SETI survey that will be vastly more complete than any previous such search,” he added.

Siemion highlighted the singular role the $100-million Breakthrough Listen Initiative has played in reinvigorating the field of SETI in recent years. Siemion also announced the latest scientific results from Listen, a SETI survey in the direction of stars where a distant civilization could observe the Earth’s passage across the sun, and the availability of nearly 2 PetaBytes of data from the Listen Initiative’s international network of observatories.

Other indicators of possible technologies include laser beams, structures built around stars to capture the star’s power output, atmospheric chemicals produced by industries, and rings of satellites similar to the ring of geosynchronous communication satellites orbiting above Earth’s equator.

“Such indicators are becoming detectable as our technology advances, and this has renewed interest in SETI searches at both government agencies and private foundations,” Siemion said.

Life forms, whether intelligent or not, also can produce detectable indicators. These include the presence of large amounts of oxygen, smaller amounts of methane, and a variety of other chemicals. Victoria Meadows, Principal Investigator for NASA’s Virtual Planetary Laboratory at the University of Washington, described how scientists are developing computer models to simulate exterrestrial environments and to help support future searches for habitable planets and life beyond the Solar System.

“Upcoming telescopes in space and on the ground will have the capability to observe the atmospheres of Earth-sized planets orbiting nearby cool stars, so it’s important to understand how best to recognize signs of habitability and life on these planets,” Meadows said, “These computer models will help us determine whether an observed planet is more or less likely to support life.”

As new programs implement the expanding technical capabilities for detecting extraterrestrial life and intelligence, it’s important to define what constitutes compelling, credible evidence, according to Jill Tarter, of the SETI Institute.

“How strong does the evidence need to be to justify claiming a discovery? Can we expect to find smoking guns? If the evidence requires many caveats, how do we responsibly inform the public,” Tarter asked.

Tarter pointed out that projects such as the University of California at San Diego’s PANOSETI visible-light and infrared search, and the SETI Institute’s Laser SETI search are being built with co-observing sites to reduce false positives. Such measures, she said, will boost confidence in reported detections, but also add to the expense of the project.

The news media also share responsibility for communicating accurately with the public, Tarter emphasized. She cited cases in recent years of “exuberant reporting” of bogus claims of SETI detections. “A real detection of extraterrestrial intelligence would be such an important milestone in our understanding of the Universe that journalists need to avoid uncritical reporting of obviously fake claims,” she said.

“As continuing discoveries show us that planets are very common components of the Universe, and we are able to study the characteristics of those planets, it’s exciting that at the same time, technological advances are giving us the tools to greatly expand our search for signs of life. We look forward to this new realm of discovery,” said Beasley, who organized the AAAS panel.

“We also look forward to the coming decade, when we hope to build a next-generation Very Large Array, which will be able to search a volume of the Universe a thousand times larger than that accessible to current telescopes — making it the most powerful radio technosignature search machine humanity has ever constructed,” Beasley added.

The National Radio Astronomy Observatory is a facility of the National Science Foundation, operated under cooperative agreement by Associated Universities, Inc.

Researchers from the University of Helsinki found that molecule BT13 has the potential to both boost levels of dopamine, the chemical that is lost in Parkinson’s, as well as protect the dopamine-producing brain cells from dying.

The results from the study, co-funded by Parkinson’s UK and published online today in the journal Movement Disorders, showed an increase in dopamine levels in the brains of mice following the injection of the molecule. BT13 also activated a specific receptor in the mouse brains to protect the cells.

Typically, by the time people are diagnosed with Parkinson’s, they have already lost 70-80 per cent of their dopamine-producing cells, which are involved in coordinating movement.

While current treatments mask the symptoms, there is nothing that can slow down its progression or prevent more brain cells from being lost, and as dopamine levels continue to fall, symptoms get worse and new symptoms can appear.

Researchers are now working on improving the properties of BT13 to make it more effective as a potential treatment which, if successful, could benefit the 145,000 people living with Parkinson’s in the UK.

The study builds on previous research on another molecule that targets the same receptors in the brain, glial cell line-derived neurotrophic factor (GDNF), an experimental treatment for Parkinson’s which was the subject of a BBC documentary in February 2019. While the results were not clear cut, GDNF has shown promise to restore damaged cells in Parkinson’s.

However, the GDNF protein requires complex surgery to deliver the treatment to the brain because it’s a large molecule that cannot cross the blood-brain barrier — a protective barrier that prevents some drugs from getting into the brain.

BT13, a smaller molecule, is able to cross the blood-brain barrier — and therefore could be more easily administered as a treatment, if shown to be beneficial in further clinical trials.

Professor David Dexter, Deputy Director of Research at Parkinson’s UK, said:

“People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms.

“One of the biggest challenges for Parkinson’s research is how to get drugs past the blood-brain barrier, so the exciting discovery of BT13 has opened up a new avenue for research to explore, and the molecule holds great promise as a way to slow or stop Parkinson’s.

“More research is needed to turn BT13 into a treatment to be tested in clinical trials, to see if it really could transform the lives of people living with Parkinson’s.”

Dr Yulia Sidorova, lead researcher on the study, said: “We are constantly working on improving the effectiveness of BT13. We are now testing a series of similar BT13 compounds, which were predicted by a computer program to have even better characteristics.

“Our ultimate goal is to progress these compounds to clinical trials in a few coming years.”

Story Source:

Materials provided by Parkinson’s UK. Note: Content may be edited for style and length.